Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.
Fiche publication
Date publication
avril 2022
Journal
Journal of neuro-oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges, Dr SCHOTT Roland
Tous les auteurs :
Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICIs) can induce adverse neurological effects. Due to its rarity as an adverse effect, meningitis has been poorly described. Therefore, meningitis diagnosis and management can be challenging for specialists. Moreover, meningitis can be an obstacle to resuming immunotherapy. Given the lack of alternatives, the possibility of reintroducing immunotherapy should be discussed on an individual basis. Here, we present a comprehensive systematic review of meningitis related to ICIs.
Mots clés
Aseptic meningitis, Immune-related adverse event, Immunotherapy, Melanoma, Reintroduction
Référence
J Neurooncol. 2022 Apr 13;: